207 related articles for article (PubMed ID: 38609887)
1. Partial recovery of peripheral blood monocyte subsets in head and neck squamous cell carcinoma patients upon radio(chemo)therapy is associated with decreased plasma CXCL11.
Idel C; Fleckner J; Plötze-Martin K; Werner L; Rades D; Theodoraki MN; Hofmann L; Huber D; Leichtle A; Hoffmann TK; Bruchhage KL; Pries R
BMC Cancer; 2024 Apr; 24(1):459. PubMed ID: 38609887
[TBL] [Abstract][Full Text] [Related]
2. 1,8-Cineol Attenuates Checkpoint Molecule PDL-1 and Adhesion Molecule CX3CR1 in Circulating Monocytes in Otitis Media Patients.
Leichtle A; Jeschke S; Plötze-Martin K; Idel C; Bruchhage KL; Pries R
J Pers Med; 2024 Mar; 14(3):. PubMed ID: 38541021
[TBL] [Abstract][Full Text] [Related]
3. Correlation of Intra-tumoral and Peripheral PD-1/PD-L1 Immunity in Head and Neck Cancer.
Idel C; Ribbat-Idel J; VON Bernuth A; Fleckner J; Rades D; Kirfel J; Sailer V; Plötze-Martin K; Bruchhage KL; Pries R
Anticancer Res; 2023 Dec; 43(12):5349-5358. PubMed ID: 38030173
[TBL] [Abstract][Full Text] [Related]
4. Plasma‑derived CD16 exosomes and peripheral blood monocytes as correlating biomarkers in head and neck cancer.
Theodoraki MN; Hofmann L; Huber D; Brunner C; Hoffmann TK; Idel C; Fleckner J; Bruchhage KL; Pries R
Oncol Lett; 2023 May; 25(5):200. PubMed ID: 37113401
[TBL] [Abstract][Full Text] [Related]
5. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
6. Association between spatial distribution of leukocyte subsets and clinical presentation of head and neck squamous cell carcinoma.
Netzer C; von Arps-Aubert V; Mačinković I; von der Grün J; Küffer S; Ströbel P; von Knethen A; Weigert A; Beutner D
Front Immunol; 2023; 14():1240394. PubMed ID: 38322012
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 expression in recurrent head and neck squamous cell carcinoma.
Delafoy A; Uguen A; Lemasson G; Conan-Charlet V; Pradier O; Lucia F; Schick U
Eur Arch Otorhinolaryngol; 2022 Jan; 279(1):343-351. PubMed ID: 33796940
[TBL] [Abstract][Full Text] [Related]
8. Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy.
Sadeghirad H; Liu N; Monkman J; Ma N; Cheikh BB; Jhaveri N; Tan CW; Warkiani ME; Adams MN; Nguyen Q; Ladwa R; Braubach O; O'Byrne K; Davis M; Hughes BGM; Kulasinghe A
Front Immunol; 2023; 14():1135489. PubMed ID: 37153589
[TBL] [Abstract][Full Text] [Related]
9. Smoking-, Alcohol-, and Age-Related Alterations of Blood Monocyte Subsets and Circulating CD4/CD8 T Cells in Head and Neck Cancer.
Idel C; Loyal K; Rades D; Hakim SG; Schumacher U; Bruchhage KL; Pries R
Biology (Basel); 2022 Apr; 11(5):. PubMed ID: 35625386
[TBL] [Abstract][Full Text] [Related]
10. Immunological features of circulating monocyte subsets in patients with squamous cell carcinoma of the head and neck.
Sakakura K; Takahashi H; Motegi SI; Yokobori-Kuwabara Y; Oyama T; Chikamatsu K
Clin Immunol; 2021 Apr; 225():108677. PubMed ID: 33476742
[TBL] [Abstract][Full Text] [Related]
11. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
12. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma.
Evrard D; Hourseau M; Couvelard A; Paradis V; Gauthier H; Raymond E; Halimi C; Barry B; Faivre S
Oncoimmunology; 2020 Nov; 9(1):1844403. PubMed ID: 33299655
[TBL] [Abstract][Full Text] [Related]
14. Hypothyroidism in Head and Neck Squamous Cell Carcinoma Patients Receiving Radiotherapy With or Without Immune Checkpoint Inhibitors.
Leddon JL; Chirra M; Frankart AJ; Agrawal A; Roof L; Trotier D; Shaikh H; Stone T; Jandarov R; Takiar V; Wise-Draper TM
Laryngoscope; 2021 Jul; 131(7):E2413-E2419. PubMed ID: 33609046
[TBL] [Abstract][Full Text] [Related]
15. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
Front Immunol; 2021; 12():645170. PubMed ID: 33897693
[TBL] [Abstract][Full Text] [Related]
16. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.
Yu D; Liu X; Han G; Liu Y; Zhao X; Wang D; Bian X; Gu T; Wen L
Cell Commun Signal; 2019 Dec; 17(1):173. PubMed ID: 31881947
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.
Starzer AM; Heller G; Tomasich E; Melchardt T; Feldmann K; Hatziioannou T; Traint S; Minichsdorfer C; Schwarz-Nemec U; Nackenhorst M; Müllauer L; Preusser M; Berghoff AS; Fuereder T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338086
[TBL] [Abstract][Full Text] [Related]
18. Programmed Cell Death-Ligand 1 in Head and Neck Squamous Cell Carcinoma: Molecular Insights, Preclinical and Clinical Data, and Therapies.
Meliante PG; Barbato C; Zoccali F; Ralli M; Greco A; de Vincentiis M; Colizza A; Petrella C; Ferraguti G; Minni A; Fiore M
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499710
[TBL] [Abstract][Full Text] [Related]
19. Differential Effects of Anti-PD-1/PD-L1 Checkpoint Inhibitors on Adhesion Molecules and Cytokine Secretion by THP-1 Monocytes.
Probst E; Franzen KF; Idel C; Plötze-Martin K; Fleckner J; Rades D; Bohnet S; Bruchhage KL; Pries R
Anticancer Res; 2023 Jun; 43(6):2445-2454. PubMed ID: 37247886
[TBL] [Abstract][Full Text] [Related]
20. Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage.
Hira-Miyazawa M; Nakamura H; Hirai M; Kobayashi Y; Kitahara H; Bou-Gharios G; Kawashiri S
Int J Oncol; 2018 Feb; 52(2):379-388. PubMed ID: 29345283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
